Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro ...
In a nationwide cohort of more than 2.5 million average-risk adults, researchers found that completing mt-sDNA screening was associated with an approximately 54% lower adjusted incidence rate of ...
Abbott announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual ...
Shares of Abbott Laboratories (ABT) have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences Corporation (EXAS), taking place at a revenue ...
Abbott's $7.4B free cash flow and 0.3x debt load contrast sharply with UnitedHealth's $16.1B free cash flow but higher leverage and government policy risk.
Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
Follow Abbott Laboratories as investors assess medical devices and diagnostics, the current catalyst, execution risks and the company evidence that may shape its next market move.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results